Streetbeat News

Products Services

JNJ

Johnson & Johnson has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending full approval for Sirturo, a treatment for multidrug-resistant tuberculosis. This marks a significant step forward in the fight against this challenging health issue.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 2:17 pm

ANVS

Annovis Bio announced that its drug Buntanetap has been found to be safe and well tolerated in recent studies, potentially impacting the company's stock positively.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 2:16 pm

CNDT

MSFT

Shares of Conduent Inc (NASDAQ:CNDT) rose after announcing a collaboration with Microsoft Corp (NASDAQ:MSFT) to use Microsoft Azure OpenAI Service for generative AI applications in healthcare claims management, customer service platforms, and fraud detection. This partnership aims to enhance quality, productivity, and cycle times for Conduent's global clients, with three pilot projects already underway.

Portfolio Pulse from Shivani Kumaresan

April 29, 2024 | 2:09 pm

RTX

RTX's Raytheon has awarded a contract to Spain's Sener for the development and production of up to 1,000 GEM-T missiles for a NATO coalition including Germany, the Netherlands, Romania, and Spain. Sener will contribute to the missile's electro-mechanical control section, enhancing Raytheon's GEM-T missile production capacity in Europe. This collaboration supports NATO and European Patriot allies, with Sener's expertise in missile actuation and control systems playing a crucial role.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 2:03 pm

AAPL

Apple Inc (NASDAQ:AAPL) is set to host a digital launch event on May 7, focusing on new developments in its iPad and iPhone lineups, with anticipated enhancements and a focus on AI at the WWDC in June. Amid a 12% stock decline in 2024, these launches are viewed as potential catalysts for a rebound, especially with AAPL's stock currently at a critical support level around $165, after fluctuating between $165 and $200 since July 2023.

Portfolio Pulse from Zaheer Anwari

April 29, 2024 | 2:03 pm

MRNA

MYNZ

PFE

mRNA technology, known for its role in COVID-19 vaccines by Pfizer and Moderna, is now promising breakthroughs in cancer diagnostics and treatment. Mainz Biomed reported significant findings from a clinical study on its ColoAlert® CRC screening test, showing high sensitivity and specificity rates. The study, involving 690 subjects across the U.S. and Europe, used novel mRNA biomarkers and a proprietary AI algorithm. Moderna, in partnership with OpenAI, is advancing mRNA medicine further by integrating AI technologies like a customized version of ChatGPT, mChat, into its operations.

Portfolio Pulse from Upwallstreet

April 29, 2024 | 2:02 pm

TSLA

Tesla Inc's Model 3 and Model Y have passed China's data security requirements, a crucial step for deploying its full self-driving (FSD) software in China. The China Association of Automobile Manufacturers confirmed the compliance of these models along with others from companies like BYD, Ideal, Lotus, Hezhong New Energy, and NIO. This development follows CEO Elon Musk's recent visit to China and a partnership with Baidu Inc for navigation data, indicating progress towards launching FSD in the Chinese market.

Portfolio Pulse from Anan Ashraf

April 29, 2024 | 2:02 pm

TFFP

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) announced positive Phase 2 trial data for Tacrolimus Inhalation Powder (TFF TAC) for lung transplant rejection prevention, presented at the ISHLT Annual Meeting. The data show TFF TAC prevents rejection with lower doses and systemic exposures than oral tacrolimus, and normalizes rejection-related gene expressions. The company plans to advance the program into potentially registrational testing.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 2:01 pm

AAPL

TSLA

Wedbush analyst Dan Ives highlighted Apple Inc. (AAPL) and Tesla Inc. (TSLA) as the only two companies successfully navigating the complex relationship between the U.S. and China, especially in the context of artificial intelligence and market challenges. Despite recent struggles in China, with Apple experiencing a 19% drop in iPhone sales and Tesla a 9% revenue decline, Ives remains optimistic about their prospects. He credits their success to superior product quality and strategic moves, such as Tesla's partnership with Baidu. Apple's shares rose 3.4%, and Tesla's surged 12.50% recently.

Portfolio Pulse from Rounak Jain

April 29, 2024 | 1:52 pm

KO

MSFT

NVDA

Microsoft Corporation (NASDAQ:MSFT) exceeded third-quarter earnings expectations with a 17% YoY revenue increase to $61.86 billion and net income of $21.94 billion. The company's Azure cloud and AI services saw significant growth, contributing to its commercial cloud revenue of $35.1 billion. Microsoft's investments in Nvidia Corporation (NASDAQ:NVDA) GPUs for AI development have led to a data center capacity challenge, mirroring Nvidia's own AI demand pressures. A new $1.1 billion agreement with The Coca-Cola Company (NYSE:KO) aims to accelerate AI transformation across Coca-Cola's global business. Despite strong performance, Microsoft anticipates near-term capacity constraints and plans a significant rise in capital expenditures for cloud infrastructure.

Portfolio Pulse from Upwallstreet

April 29, 2024 | 1:51 pm